Table 3 Characteristics of screening participants and of nonparticipants who were diagnosed with lung cancer (LC)
| Â | Participants with LC (n = 67) | Nonparticipants with LC (n = 178) | P |
|---|---|---|---|
Age, median (IQR) | 66 (60-72) | 69 (61-74) | 0.196 |
Male/female (ratio) | 60/7 (8.6) | 161/17 (9.5) | 0.834 |
Pack-years, median (IQR) | 48 (36-68)a | 49 (36-66)b | 0.768 |
Histologically confirmed LC, n (%) | 63 (94%) | 148 (83%) | 0.047 |
   Adenocarcinoma, n (%) | 18 (29%) | 51 (34%) |  |
   Squamous cell carcinoma, n (%) | 27 (43%) | 54 (37%) | 0.573 |
   Other NSCLC, n (%) | 7 (11%) | 25 (17%) |  |
   SCLC, n (%) | 11 (17%) | 18 (12%) |  |
Stage of LC at diagnosis c, d | Â | Â | Â |
   I, n (%) | 21 (32%) | 28 (17%) |  |
   II, n (%) | 3 (5%) | 10 (6%) |  |
   IIIA, n (%) | 9 (14%) | 21 (13%) | 0.078 |
   IIIB-IV and extensive SCLC, n (%) | 32 (49%) | 104 (64%) |  |
Follow-up months, median (range) e | 95 (49-161) | 104 (55-151) | 0.962 |